Yuliya Filina

Dr. Yuliya Filina

Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan’, Russia
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Cellular Signalling
Verified
Journal Article
Closed access
YFYuliya Filina
Yuliya Filina
AGAida Gabdoulkhakova
Aida Gabdoulkhakova
VSValentina G. Safronova
Valentina G. Safronova

17 January 2025 in Diseases
Verified
Journal Article
Open access
PDF file
AAAlmaz A. Akhunzianov
Almaz A. Akhunzianov
Elvira RozhinaElvira Rozhina
Elvira Rozhina
YFYuliya Filina
Yuliya Filina
Albert A RizvanovAlbert A Rizvanov
Albert A Rizvanov
Regina R. MiftakhovaRegina R. Miftakhova
Regina R. Miftakhova
Radiation therapy or radiotherapy is a medical treatment that uses high doses of ionizing radiation to eliminate cancer cells and shrink tumors. It works by targeting the DNA within the tumor cells restricting their proliferation. Radiotherapy has been used for treating cancer for more than 100 years. Along with surgery and chemotherapy, it is one of the three main and most common approaches used in cancer therapy. Nowadays, radiotherapy has become a standard treatment option for a wide range of cancers around the world, including lung, breast, cervical, and colorectal cancers. Around 50% of all patients will require radiotherapy, 60% of whom are treated with curative intent. Moreover, it is commonly used for palliative treatment. Radiotherapy provides 5-year local control and overall survival benefit in 10.4% and 2.4% of all cancer patients, respectively. The highest local control benefit is reported for cervical (33%), head and neck (32%), and prostate (26%) cancers. But no benefit is observed in pancreas, ovary, liver, kidney, and colon cancers. Such relatively low efficiency is related to the development of radiation resistance, which results in cancer recurrence, metastatic dissemination, and poor prognosis. The identification of radioresistance biomarkers allows for improving the treatment outcome. These biomarkers mainly include proteins involved in metabolism and cell signaling pathways.

11 February 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MZMariia A. Zolotykh
Mariia A. Zolotykh
LMLeysan A. Mingazova
Leysan A. Mingazova
YFYuliya Filina
Yuliya Filina
NBNataliya L. Blatt
Nataliya L. Blatt
ANAlfiya I. Nesterova
Alfiya I. Nesterova
Regina R. MiftakhovaRegina R. Miftakhova
Regina R. Miftakhova

Verified
Journal Article
Open access
PDF file
DCDaria Chulpanova
Daria Chulpanova
TPTamara V. Pukhalskaia
Tamara V. Pukhalskaia
ZGZarema Gilazieva
Zarema Gilazieva
YFYuliya Filina
Yuliya Filina
MMMilana N. Mansurova
Milana N. Mansurova
VSValeriya Solovyeva
Valeriya Solovyeva
Tumor-necrosis-factor-associated apoptosis-inducing ligand (TRAIL) is one of the most promising therapeutic cytokines that selectively induce apoptosis in tumor cells. It is known that membrane vesicles (MVs) can carry the surface markers of parental cells. Therefore, MVs are of interest as a tool for cell-free cancer therapy. In this study, membrane vesicles were isolated from TRAIL-overexpressing mesenchymal stem cells using cytochalasin B treatment (CIMVs). To evaluate the antitumor effect of CIMVs-TRAIL in vivo, a breast cancer mouse model was produced. The animals were intratumorally injected with 50 µg of native CIMVs or CIMVs-TRAIL for 12 days with an interval of two days. Then, tumor growth rate, tumor necrotic area, the expression of the apoptosis-related genes CASP8, BCL-2, and BAX and the level of CASP8 protein were analyzed. A 1.8-fold increase in the CAS8 gene mRNA and a 1.7-fold increase in the CASP8 protein level were observed in the tumors injected with CIMVs-TRAIL. The expression of the anti-apoptotic BCL-2 gene in the CIMV-TRAIL group remained unchanged, while the mRNA level of the pro-apoptotic BAX gene was increased by 1.4 times, which indicated apoptosis activation in the tumor tissue. Thus, CIMVs-TRAIL were able to activate the extrinsic apoptosis pathway and induce tumor cell death in the breast cancer mouse model.

7 September 2022 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
YFYuliya Filina
Yuliya Filina
ITI.V. Tikhonova
I.V. Tikhonova
AGA.G. Gabdoulkhakova
A.G. Gabdoulkhakova
ARA.A. Rizvanov
A.A. Rizvanov
VSV.G. Safronova
V.G. Safronova

22 March 2024 in Translational Oncology
Verified
Journal Article
Open access
ARAigul R. Rakhmatullina
Aigul R. Rakhmatullina
MZMariia A. Zolotykh
Mariia A. Zolotykh
YFYuliya Filina
Yuliya Filina
RMRimma N. Mingaleeva
Rimma N. Mingaleeva
ASAisylu R. Sagdeeva
Aisylu R. Sagdeeva
Regina R. MiftakhovaRegina R. Miftakhova
Regina R. Miftakhova
Tumor employs non-cancerous cells to gain beneficial features that promote growth and survival of cancer cells. Despite intensive research in the area of tumor microenvironment, there is still a lack of reliable and reproducible in vitro model for tumor and tumor-microenvironment cell interaction studies. Herein we report the successful development of a heterogeneous cancer-stroma sphere (CSS) model composed of prostate adenocarcinoma PC3 cells and immortalized mesenchymal stem cells (MSC). The CSS model demonstrated a structured spatial layout of the cells, with stromal cells concentrated at the center of the spheres and tumor cells located on the periphery. Significant increase in the levels of VEGFA, IL-10, and IL1a has been detected in the conditioned media of CSS as compared to PC3 spheres. Single cell RNA sequencing data revealed that VEGFA was secreted by MSC cells within heterogeneous spheroids. Enhanced expression of extracellular membrane (ECM) proteins was also shown for CSS-derived MSCs. Furthermore, we demonstrated that the multicellular architecture altered cancer cell response to chemotherapeutic agents: the inhibition of sphere formation by topotecan was 74.92 ± 4.56 % for PC3 spheres and 45.95 ± 7.84 % for CSS spheres (p < 0.01), docetaxel showed 37,51± 20,88 % and 15,67± 14,08 % inhibition, respectively (p < 0.05). Thus, CSS present an effective in vitro model for examining the extracellular matrix composition and cell-to-cell interactions within the tumor, as well as for evaluating the antitumor activity of drugs.